Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Accreditation status of the UFS School of Medicine
2016-06-14

This communication is a factual correction of the misinformation and accompanying hysteria that appeared in a local newspaper this past week on the accreditation status of programmes in the Faculty of Health Sciences’ School of Medicine. Here are the facts:
 
1. The flagship programme of the School of Medicine, the MB ChB, was fully accredited by the Health Professions Council of South Africa (HPCSA) through the year 2020. This is the maximum accreditation status that any programme can achieve, and the UFS leadership is extremely pleased with this outcome, as it expresses confidence in the work done by our academics in the School of Medicine. Not only was the basic medical training for new doctors fully accredited, the HPSCA approved an increase in the number of trainee doctors from 140 to 160, and also approved additional training sites in Trompsburg and Kimberley.
 
2. The honours programmes of the School of Medicine received full accreditation as well.
 
3. All the master’s degree programmes in the School of Medicine also received accreditation. The UFS is especially pleased with the significant improvements in the Department of Cardiology, which now has a full complement of staff under the leadership of the highly regarded cardiologist, Prof Makoali Makotoko.
 
4. Four master’s programmes received provisional accreditation, which means that (a) these programmes continue to be taught and (b) outstanding issues, such as inadequate staffing, must be fixed. It does not mean that these programmes will be or are likely to be discontinued.
 
5. It is a fact that staff retire or resign in all schools and departments of any university. It is also true that these departures offer opportunities to bring new academic and professional staff into the UFS. In fact, for the first time virtually every department in the School of Medicine now has a full-time Head of Department and 46 new staff were appointed since January 2015.
 
6. The main employer of academic staff in the School of Medicine is the provincial Department of Health (DoH), and the UFS works very closely and persistently with the Free State DoH to ensure that vacant posts are filled.
 
7. The attacks on the integrity of the outgoing Head of the School of Medicine were malicious. Prof Alan St Clair Gibson did not resign ‘overnight’; his departure has nothing to do with the accreditation status of the School – in fact, he can be proud of this achievement; and he effectively takes up a promotion post in New Zealand as academic Dean at the University of Waikato. Prof St Clair Gibson will be remembered for his leadership in transformation, especially regarding staff and student equity in the School of Medicine, and for securing our programme accreditation. For this, the university is deeply grateful.

Released by:
Lacea Loader (Director: Communication and Brand Management)
Telephone: +27(0)51 401 2584 | +27(0)83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27(0)51 444 6393

 

 



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept